Both autologous bone marrow mononuclear cell and peripheral blood progenitor cell therapies similarly improve ischaemia in patients with diabetic foot in comparison with control treatment
Jazyk angličtina Země Anglie, Velká Británie Médium print
Typ dokumentu srovnávací studie, klinické zkoušky kontrolované, časopisecké články, práce podpořená grantem
PubMed
23390092
DOI
10.1002/dmrr.2399
Knihovny.cz E-zdroje
- Klíčová slova
- critical limb ischaemia, diabetic foot, stem cell therapy,
- MeSH
- antigeny CD34 metabolismus MeSH
- autologní transplantace MeSH
- cytokiny krev MeSH
- diabetická noha imunologie patofyziologie chirurgie terapie MeSH
- dolní končetina MeSH
- ischemie etiologie prevence a kontrola MeSH
- leukocyty mononukleární imunologie metabolismus transplantace MeSH
- lidé středního věku MeSH
- lidé MeSH
- následné studie MeSH
- senioři MeSH
- transkutánní měření krevních plynů MeSH
- transplantace kostní dřeně * škodlivé účinky imunologie MeSH
- transplantace periferních kmenových buněk * škodlivé účinky MeSH
- záchrana končetiny * MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky kontrolované MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
- Názvy látek
- antigeny CD34 MeSH
- cytokiny MeSH
BACKGROUND: The aim of our study was to compare the effect of bone marrow mononuclear cell and peripheral blood progenitor cell therapies in patients with diabetic foot disease and critical limb ischaemia unresponsive to revascularization with conservative therapy. METHODS: Twenty-eight patients with diabetic foot disease (17 treated by bone marrow cells and 11 by peripheral blood cell) were included into an active group and 22 patients into a control group without cell treatment. Transcutaneous oxygen pressure and rate of major amputation, as the main outcome measures, were compared between bone marrow cells, peripheral blood cell and control groups over 6 months; both cell therapy methods were also compared by the characteristics of cell suspensions. Possible adverse events were evaluated by changes of serum levels of angiogenic cytokines and retinal fundoscopic examination. RESULTS: The transcutaneous oxygen pressure increased significantly (p < 0.05) compared with baseline in both active groups after 6 months, with no significant differences between bone marrow cells and peripheral blood cell groups; however, no change of transcutaneous oxygen pressure in the control group was observed. The rate of major amputation by 6 months was significantly lower in the active cell therapy group compared with that in the control group (11.1% vs. 50%, p = 0.0032), with no difference between bone marrow cells and peripheral blood cell. A number of injected CD34+ cells and serum levels of angiogenic cytokines after treatment did not significantly differ between bone marrow cells and peripheral blood cell. CONCLUSIONS: Our study showed a superior benefit of bone marrow cells and peripheral blood cell treatments of critical limb ischaemia in patients with diabetic foot disease when compared with conservative therapy. There was no difference between both cell therapy groups, and no patient demonstrated signs of systemic vasculogenesis.
Citace poskytuje Crossref.org
The Use of Autologous Cell Therapy in Diabetic Patients with Chronic Limb-Threatening Ischemia
Cell Therapy of Severe Ischemia in People with Diabetic Foot Ulcers-Do We Have Enough Evidence?
